Bibliography
- DUNN GP, BRUCE AT, IKEDA H, OLD LI, SCHREIBER RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Iminunol. (2002) 3 (11):991–998.
- PARDOLL DM: Cancer vaccines. Nat. Med. (1998) 4(5Suppl.):525–531.
- •An in-depth review of the contemporary cancer vaccine approaches aimed at exposing cancer antigens to the cellular arm of the irmrtune system and the prospects for therapeutic cancer vaccines.
- OVERWIJK WW, RESTIFO NP: Creating therapeutic cancer vaccines: notes from the battlefield. Trends Inununol. (2001) 22(1):5–7.
- •A concise review of the new challenges faced in the field of tumour immunology and the future direction of cancer vaccine research.
- MONZAVI-KARBASSI B, KIEBER-EMMONS T: Current conceptsin cancer vaccine strategies. Biotechniques (2001) 30(1):170–172,174,176.
- •A critical review of current perspectives and future strategies for active specific immunotherapy of cancers, particularly the use of tumour-derived HSPs and carbohydrate antigens in cancer vaccines.
- DE GRUIJL TD, CURIEL DT: Cancer vaccine strategies get bigger and better. Nat. Med. (1999) 5(10):1124–1125.
- OFFRINGA R, VAN DER BURG SH, OSSENDORP F, IDES RE, MELIEF CJ: Design and evaluation of antigen-specific vaccination strategies against cancer. Carr. Opin. Iminunol. (2000) 12(5):576–582.
- ••A comprehensive review on the need forvaccine formulations comprising defined tumour antigens and the importance of accurate methodologies for the evaluation of vaccine-induced T cell responses.
- FINN OJ: Cancer vaccines: between the idea and the reality. Nat. Rev. brununol. (2003) 3(8):630–641.
- ••An excellent review on the current statusand potential challenges in the development of vaccines in general and cancer vaccines in particular.
- WALDMANN TA: Immunotherapy: past, present and future. Nat. Med. (2003) 9(3):269–277.
- ••An excellent review on the highlights of thepast achievements and future strategies in the development of irmrtunotherapies.
- SCHULER G, SCHULER-THURNER B, STEINMAN RM: The use of dendritic cells in cancer immunotherapy. Curt: Opin. Iminunol. (2003) 15(2):138–147.
- ••A comprehensive review on the mostimportant findings and some outstanding research questions pertinent to the DC-based cancer vaccines.
- KIESSLING R, PAWELEC G, WELSH RM, BARRY JD, FERRONE S: Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies. Mol. Med. Today (2000) 6(9):344–346.
- WHELAN M, WHELAN J, RUSSELL N, DALGLEISH A: Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today (2003) 8(6):253–258.
- PARMIANI G, CASTELLI C, DALERBA P et al.: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? Natl. Cancer Inst. (2002) 94(11):805–818.
- ••A comprehensive review on the features, thecurrent obstacles and potential solutions to increase the clinical efficacy of TAA peptide-based vaccination for cancer patients.
- JAGER E, JAGER D, KNUTH A: Clinical cancer vaccine trials. Can: Opin. brununol. (2002) 14(2):178–182. A summary review on the specific approaches to cancer vaccination and the immunological effects observed so far in the clinical cancer vaccine trials.
- SRIVASTAVA PK, AMATO RI: Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine (2001) 19(17-19):2590–2597.
- ••An excellent review on both basic andclinical researches on the use of HSPs for vaccination against cancers and infectious diseases.
- BELLONE M, IEZZI G, IMRO MA, PROTTI MP: Cancer immunotherapy: synthetic and natural peptides in the balance. Iritinunol Today(1999) 20(10):457–462.
- COULIE PG, BRUGGEN P: T cell responses of vaccinated cancer patients. Curc Opin. Itninunol. (2003) 15(2):131–137.
- BHARDWAJ N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol. Med. (2001) 7(9):388–394.
- DALLAL RM, LOTZE MT: The dendritic cell and human cancer vaccines. Can: Opin. brununol. (2000) 12(5):583–588.
- GOLDMAN B: Turning a tumour into its own worst enemy. Drug Discov. Today (2003) 8(11):471–472.
- CUI Y, KELLEHER E, STRALEY E et al.: Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. (2003) 9(7):952–958.
- ••An excellent paper reporting the feasibilityof using bone marrow transplantation with antigen gene-modified haematopoietic stem cells for efficient expression of TAAs in a large population of APCs, expansion and activation of specific T cells, and protection against an aggressive established tumour.